PUBLICAÇÕES científicas

Recombinant AAV integration is not associated with hepatic genotoxicity in non-human primates and patients

Gil-Farina I (1), Fronza R ()1, Kaeppel C (1,2), Lopez-Franco E (3), Ferreira V (4), D'Avola D [ES] (5,6), Benito A [ES] (5,6), Prieto J (5,6), Petry H (4), Gonzalez-Aseguinolaza G (3,6), Schmidt M (1).
(1) Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
(2) Current address: Eurofins Medigenomix GmbH, Ebersberg, Germany.
(3) Department of Gene Therapy and Hepatology, Center for Applied Medical Research, Pamplona, Spain.
(4) Research and Development, uniQure B.V., Amsterdam, The Netherlands.
(5) Hepatology Unit, Clinica Universidad de Navarra, Pamplona, Spain.
(6) Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain. 

Revisão:Molecular Therapy

Data: 7/Mar/2016

Radiología [ES] Hepatologia


Recombinant adeno-associated viral vectors (rAAV) currently constitute a real therapeutic strategy for the sustained correction of diverse genetic conditions.

Though a wealth of preclinical and clinical studies have been conducted with rAAV, the oncogenic potential of these vectors is still controversial, particularly when considering liver-directed gene therapy. Few preclinical studies and the recent discovery of incomplete wild-type AAV2 genomes integrated in human hepatocellular carcinoma biopsies have raised concerns on rAAV safety.

In the present study we have characterized the integration of both complete and partial rAAV2/5 genomes in non-human primate tissues and clinical liver biopsies from a trial aimed to treat acute intermittent porphyria.

We applied a new multiplex linear amplification-mediated PCR assay capable of detecting integration events that are originated throughout the rAAV genome. The integration rate was low both in non-human primates and patient's samples.

Importantly, no integration clusters or events were found in genes previously reported to link rAAV integration with hepatocellular carcinoma development, thus showing the absence of genotoxicity of a systemically administered rAAV2/5 in a large animal model and in the clinical context.

CITAÇÃO DO ARTIGO  Mol Ther. 2016 Mar 7. doi: 10.1038/mt.2016.52

talvezlhe interesse


A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra


Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra